Tumor Lysis Syndrome

Pediatr Rev. 2020 Jan;41(1):20-26. doi: 10.1542/pir.2018-0243.
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Humans
  • Leukocyte Count
  • Risk Assessment
  • Risk Factors
  • Tumor Lysis Syndrome* / diagnosis
  • Tumor Lysis Syndrome* / etiology
  • Tumor Lysis Syndrome* / therapy

Substances

  • Antineoplastic Agents